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Cuprophan hemodialysis membranes can be heparinized
using N,N8-carbonyldiimidazole (CDI) as a coupling agent.
In this study, the characteristics of heparinized Cuprophan
membranes have been evaluated. After immobilization, hep-
arin partially retained its biologic activity. An anticoagulant
activity of 12.4 ± 4.2 mU/cm2 was measured using a throm-
bin inactivation assay. Immobilized heparin also displayed
an anti-complement activity. After contact with human se-
rum, heparinized Cuprophan induced no generation of sig-
nificant amounts of fluid phase terminal complement com-
plex (TCC), whereas untreated Cuprophan induced the gen-
eration of substantial amounts of TCC. Heparinization did
not affect the permeability of Cuprophan for model solutes
with molecular weights up to 12,000 g/mol except for sul-
fobromophthalein sodium salt. The permeability of Cupro-
phan for sulfobromophthalein sodium salt was slightly de-
creased after heparinization. The ultrafiltration rate of Cu-
prophan increased by about 30% after heparinization,
probably owing to an increased swelling of the membrane in
water. Heparinized Cuprophan incubated in phosphate-
buffered saline at 37°C showed some release of heparin.
These amounts of released heparin, however, were very low
as compared to the amounts of heparin which are systemi-
cally administered during clinical hemodialysis treatment. It
is concluded that Cuprophan membranes heparinized by
means of the CDI-activation procedure are highly promising
for application in hemodialyzers to be used for the treatment
of patients with reduced or without systemic administration
of heparin. © 1997 John Wiley & Sons, Inc.
INTRODUCTION
In current clinical practice, membranes most fre-
quently used for hemodialysis are based on cellulose.
Advantages of this type of membrane over recently
developed synthetic membranes such as polyacryloni-
trile copolymer, poly(methyl methacrylate), and poly-
sulfon are its relatively low cost, optimal water per-
meability, and extensive clinical experience with the
material.1,2 The main disadvantage is its relatively
poor blood compatibility, which is expressed by a
rather strong activation of the coagulation and
complement system and a drop in the leukocyte
count.1,3–5
Heparin is administered to uremic patients treated
with hemodialysis to avoid complications associated
with blood–material interactions.2 A systemic admin-
istration of heparin, however, may cause undesired
side effects such as internal hemorrhages and, even-
tually, osteoporoses.6,7
An often-applied strategy to improve the blood
compatibility of blood-contacting materials is to im-
mobilize heparin onto their surfaces.1,7–9 Immobilized
heparin may act as an anticoagulant for blood and an
inhibitor of the complement system at the site where it
is required while the disadvantages of systemic ad-
ministration are avoided. The heparin–material link-
age can be either physical, ionic, or covalent.1,7,9,10
With physical or ionic bonding, immobilized heparin
may easily be released from the surface.7,9,11,12 For he-
modialysis this release is undesired because a large
amount of heparin may enter the blood, eventually
leading to the same disadvantages as systemic hepa-
rinization. Furthermore, release of heparin may
gradually reduce the blood compatibility of the mem-
brane during hemodialysis. Covalent bonds are more
stable. Many techniques have been developed to
couple heparin covalently to biomaterials.1,7,9,11–13
Most of them are based on a two-step procedure
whereby the biomaterial is first activated by a bi- or
trifunctional agent, after which heparin is added to
form the heparin–material linkage.14,15 The use of bi-
or trifunctional agents may lead to crosslinking of the*To whom correspondence should be addressed.
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material. For hemodialysis membranes, crosslinking is
unwanted because it may reduce the permeability of
the membrane.
Engbers1 developed an alternative procedure for the
heparinization of Cuprophan hemodialysis mem-
branes. Heparin is first reacted with N,N8-carbonyldi-
imidazole (CDI). Subsequently, the activated product
is contacted with the membrane by which a covalent
coupling between heparin and the membrane is estab-
lished. In a previous study it was shown that heparin-
ization of Cuprophan by means of the CDI-activation
procedure does not affect the permeability of the
membrane for urea, indicating that crosslinking of the
membrane is avoided.16
In the present study, the properties of Cuprophan
heparinized by means of the CDI-activation procedure
are evaluated. The biologic activity of immobilized
heparin is investigated. Furthermore, the effects of
heparinization of the permeability of the membrane
and the stability of the heparin–Cuprophan linkage
are studied.
MATERIALS AND METHODS
Materials
Cuprophan 150M was a gift of AKZO Nobel (Wup-
pertal, Germany). Formamide (synthesis grade;
Merck, Darmstadt, Germany) was purified and dehy-
drated according to a method described by Verhoek et
al.17 and stored beneath a blanket of dry nitrogen.
Heparin from porcine intestinal mucosa (activity: 165
U/mg) was purchased from Diosynth (Oss, The Neth-
erlands). Heparin also from procine intestinal mucosa
of which 55–60% of the sodium ions was substituted
by benzyltrimethylammonium ions (heparin-triton B)
was purchased from HBG (Enschede, The Nether-
lands). Human antithrombin III (AT III; Sigma Chemi-
cal Company, St. Louis, MO) was purified using a
heparin–Sepharose column18,19 (Sigma Chemical
Company). Bovine albumin (Alb), creatinine, human
thrombin, sulfobromophthalein sodium salt (SBP),
and vitamin B12 (Vit B12) were purchased from Sigma.
Chromogenic substrate S2238 was purchased from
Chromogenix (Mo¨lndal, Sweden). Polyethylene glycol
(6000 g/mol) (PEG) was purchased from Fluka Che-
mie (Buchs, Switzerland). PTT reagent was obtained
from Boehringer (Mannhein, Germany). CPDA-1
plasma was purchased from the Rode Kruis Bloed-
bank Twente-Achterhoek (Enschede, The Nether-
lands). Phosphate-buffered saline (pH: 7.4) (PBS) was
purchased from NPBI (Emmercompascuum, The
Netherlands). CDI, cytochroom C, D (+) glucose, gla-
cial acetic acid, glycerol, inulin, NaCl, Na2HPO4,
NaH2PO4, resorcinol, sucrose, toluidine blue O zinc
chloride double salt, tris(hydroxymethyl)-ammonium
methane (Tris), and urea (all of analytic grade) were
purchased from Merck. A TCC ELISA was purchased
from Quidel Corporation (Alkmaar, The Netherlands).
All chemicals were used without further purification
except when mentioned.
Heparinization of Cuprophan
Cuprophan was heparinized as described before
(Fig. 1).1 Briefly, heparin-triton B was dissolved in dry
formamide (heparin concentration: 0.20 g/mL) and
subsequently activated with CDI (weight ratio hepa-
rin/CDI = 10) at ambient temperature. After 1 h, the
reaction mixture was transferred to Cuprophan mem-
branes, which were thoroughly prerinsed with form-
amide to remove glycerol and water. After 2 days of
immobilization at ambient temperature, the mem-
branes were thoroughly rinsed with demineralized
water and then with aqueous 4M NaCl. Subsequently,
the membranes were thoroughly rinsed with demin-
eralized water, soaked in a 10 wt % solution of glyc-
erol in demineralized water, and then dried by air
exposure. Treatment of the membranes with an aque-
ous glycerol solution before drying is necessary to pre-
vent an irreversible collapse of pores.20 Before the
membranes were subjected to further testing, they
were incubated in water or PBS at 4°C for 16 h to
remove glycerol. The immobilization procedure
yielded membranes with 60–80% mg immobilized
heparin/cm2 membrane surface area as determined
by means of a toluidine blue staining procedure as
described by Smith et al.21 and modified for our pur-
poses.22,23
Anticoagulant activity of immobilized heparin
The antithrombin activity of heparin immobilized
onto Cuprophan was investigated by means of a
thrombin inactivation assay developed by Chandler et
al.24 This assay is based on two competitive reactions.
The first reaction is heparin-catalyzed inactivation of
thrombin by AT III. The seond reaction is thrombin-
catalyzed splitting of the chromogenic substrate S2238
into a peptide and p-nitroaniline. The extinction of the
latter yellow compound can be measured spectropho-
tometrically.
A buffer consisting of an aqueous solution of 50
mmol/L Tris, 1.0 g/L PEG, 1.0 g/L BSA, and 150
mmol NaCl adjusted to pH 8.4 was prepared. The
buffer was used for the preparation of a substrate S2238
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(2.0 mg/mL)/AT III (70 mU/ml) solution, a thrombin
solution (0.4 U/mL), and a series of solutions of vari-
ous heparin concentrations (0–0.4 U/mL). Membranes
were cut into discs with a diameter of 5 mm and
placed into wells of a 96-well plate containing 150 mL
of substrate/AT III and 40 mL of buffer solution. For
the determination of a calibration curve, 150 mL of
substrate/AT III solution and 40 mL of heparin solu-
tions were added to other wells. The reactions were
initiated by adding 50 mL of thrombin solution to the
wells after which the well plate was shaken. After 10
min, the reactions were quenched by adding 70 mL 40
vol % acetic acid. Subsequently, 200 mL of the resultant
mixture was transferred into empty wells and the ex-
tinction was measured at 405 nm. The reactions were
carried out at room temperature. The results of experi-
ments using solutions of known heparin concentra-
tions were used to determine the activity of heparin
immobilized onto Cuprophan. The experiments were
performed at least four times.
Anticomplement activity of immobilized heparin
Blood was drawn from healthy volunteers into
polypropylene tubes and allowed to clot for 1 h at
room temperature. Subsequently, the samples were
centrifuged at 2000 × g for 15 min at 4°C, after which
the serum was separated from the clot by decantation.
The serum was quickly frozen using liquid nitrogen
and then placed at −20°C until use.
Prior to the complement activation assay, serum
was thawed at 37°C and stored on ice. Membranes
were cut into discs with a diameter of 5 mm. Ten of
these membranes were placed in a polystyrene tube.
Subsequently, 500 mL of serum was added to the tube.
Polystyrene tubes which did not contain membranes
were used as negative controls. Thereafter, the tubes
were gently shaken at 37°C. At different time intervals
samples of the serum were taken. The TCC concentra-
tions of the samples were determined by means of an
ELISA according to the recommendations of the
manufacturer. The experiments were performed four
times.
Effect of heparinization on the permeability
of Cuprophan
The effect of heparinization on the permeability of
Cuprophan for solutes of different molecular weights
(Table I) was investigated using a Minitan-S ultrafil-
tration system (Millipore, Etten-Leur, The Nether-
lands) equipped with a peristaltic pump (Watson-
Marlow Ltd., Cornwall, UK) or using a minibatch dia-
lyzer (only for testing the permeability for cytochrome
C). The experiments were carried out at 37°C. In all
cases, except for PO4
3−, solutions of the solutes in PBS
were used as feed and PBS as dialysate. In case of
PO4
3−, solutions of NaH2PO4 and Na2HPO4 in aque-
ous 0.42 wt % NaCl were used as feed and aqueous
0.42 wt % NaCl as dialysate. Solutions containing a
mixture of urea, creatinine, and glucose and solutions
containing a mixture of SBP and Vit B12 were also
used. Preliminary experiments showed that the per-
meability of the membranes for one of these solutes
was not affected by the presence of the other solute(s)
in the same solution (data not shown). The starting
concentrations of the solutes of the various feed solu-
tions are listed in Table I. Samples were taken from the
dialysate at different time intervals (except for PO4
3−).
The samples were analyzed as follows. Glucose: The
concentration was determined using a Cobas Bio au-
tomatic analyzer and a glucose kinetic ultra violet
(UV) test kit. Urea and creatinine: the concentrations
were determined using a Hitachi 717 automatic ana-
lyzer and kinetic UV test kits for urea and creatinine.
Sucrose and inulin25: 1 mL of the sample was added to
5 mL of a 0.167 g/mL solution of resorcinol in aqueous
4N HCl. The resultant mixture was heated to 100°C for
15 min. After cooling to ambient temperature, the ex-
tinction was measured at 480 nm. Vit B12: the extinc-
tion was measured at 360 nm. SBP: the sample was
1/1 (v/v) diluted with aqueous 0.01 N NaOH, after
which the extinction of the mixture was measured at
578 nm. PO4
3−: the conductivity of the dialysate was
measured in situ by means of a Philips PW 9527 con-
ductivity flow cell. Cytochrome C: the extinction was
Figure 1. Heparinization of Cuprophan by means of a CDI
activation procedure. (a) Activation reactions of heparin
with CDI. (b) Immobilization reactions of CDI-activated
heparin onto Cuprophan.
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measured at 409 nm. Calibration curves were used to
determine the concentrations of the solutes.
The mass transfer coefficient, Ko, was calculated us-
ing the formula as derived by Smith et al.26:
−Ln (DCt/DCo) = Ko × A × t × (1/V1 + 1/V2),
where DCt and DCo are the concentration differences of
the solutes over the membrane at times t and 0, re-
spectively; A is the membrane surface area; t is the
dialysis time; and V1 and V2 are the volumes of feed
and dialysate respectively. All experiments were per-
formed at least four times.
Effect of heparinization on the ultrafiltration
characteristics of Cuprophan
The water permeability of nonheparinized and hep-
arinized Cuprophan was determined with an Amicon
8050 ultrafiltration cell (Amicon, Capelle aan de Ijssel,
The Netherlands). The membrane was positioned in
the ultrafiltration cell, after which the cell was filled
with deionized water. Subsequently, a pressure of 3
bar was applied. After 1–2 h of equilibration, the water
flow through the membrane was measured for 2–4 h.
The measurements were performed in triplicate.
Stability of heparin–Cuprophan linkage in PBS
Heparinized Cuprophan was placed in tubes con-
taining PBS which was supplemented with NaN3 (fi-
nal concentration: 0.02 wt %) to prevent bacterial
growth. The tubes were placed in a water bath of 37°C
and gently shaken. At different time intervals,
samples of PBS were taken. The amount of heparin
released into PBS was determined by means of an ac-
tivated partial thromboplastin time (APTT) assay.
Therefore, fresh-frozen human CPDA-1 plasma was
thawed at 37°C and stored on ice. To 50 mL of the
release medium, 50 mL plasma was added and thor-
oughly mixed at 37°C. After 1 min, 50 mg PTT reagent
was added. The resulting suspension was mixed for 3
min at 37°C. Thereafter, 50 mL of an aqueous 20 mM
CaCl2 solution was added. The suspension was mixed
again and the coagulation time was determined with a
coagulatometer (LC-6; Lode, Groningen, The Nether-
lands). A calibration curve, obtained using solutions
of heparin in PBS of known activities, was applied to
calculate the release of heparin from the membrane.
The measurements were performed eight times.
RESULTS AND DISCUSSION
With the CDI-activation procedure, 60–80 mg hepa-
rin/cm2 membrane surface was immobilized. Bau-
mann et al.,11 Schmitt et al.,12 and Holland et al.,27 who
studied the ionic binding of heparin onto cationized
cellulosic membranes [N,N8-diethylaminoethyl cellu-
lose and 2-(hydroxy-3-trimethylammoniumchloride)
propyl cellulose] found comparable amounts of im-
mobilized heparin. These very high amounts of im-
mobilized heparin are remarkable. If a monolayer of
heparin would have formed on the surface of the
membranes, a density of only 0.1–0.2 mg/cm2 or 2.0
mg/cm2 is estimated for heparin immobilized with a
side-on or an end-on orientation, respectively.28 Water
swollen Cuprophan has pores with a diameter up to
25 Å.29 Most likely, heparin is also immobilized in the
pores of the membrane.
The anticoagulant activity of immobilized heparin
was evaluated by measuring the inactivation of
thrombin in a chromogenic assay. In this assay, hep-
arinized Cuprophan displayed an anticoagulant activ-
ity of 12.4 ± 4.2 mU/cm2, whereas untreated Cupro-
phan showed no significant activity (0.5 ± 0.6 mU/
cm2). These results show that heparin immobilized by
means of the CDI-activation procedure at least par-
tially retained its original anticoagulant activity. As
mentioned above, heparin was partially immobilized
in the pores of the membrane. It is expected that this
part of immobilized heparin did not contribute to the
anticoagulant activity because the pores are too small
to allow for the penetration of AT III and thrombin.
Therefore, only heparin immobilized at the surface
will display anticoagulant activity. Depending on its
orientation, a maximal activity of 16.5–350 mU/cm2 is
calculated for a monolayer of immobilized heparin.
This maximal activity was not reached for heparinized
Cuprophan. Two reasons may account for this. First, a
monolayer of immobilized heparin at the surface may
not have formed. Second, the activity of heparin was
reduced owing to immobilization. A reduction of the
activity is usually observed upon immobilization,10,30
TABLE I
Molecular Weights and Starting Concentrations in the
Feed of Solutes Used to Test the Permeability
of the Membranes
Solute
Molecular Weight
(g/mol)
Starting Concentration
in Feed (wt %)
Urea 60 0.76
Phosphate 96 *
Creatinine 113 0.035
Glucose 180 3.45
Sucrose 342 0.2
SBP 835 0.02
Vitamin B12 1355 0.02
Inulin 5200 0.2
Cytochrome C 12,000 1.0
*Mixture of Na2HPO4 (0.9 wt %) and NaH2PO4 (0.15
wt %).
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which can be ascribed to a restricted mobility of sur-
face-bound heparin as compared to unbound heparin.
As a consequence, the exposure of binding sites of
heparin for AT III and thrombin is limited.
Complement activation induced by the membranes
was determined by measuring the concentration of
fluid phase TCC. As shown in Figure 2, untreated Cu-
prophan induced the generation of substantial
amounts of fluid-phase TCC, which strongly increased
during 3 h of incubation. The generation of fluid-
phase TCC induced by heparinized Cuprophan was
much lower. The concentration of TCC in serum in the
presence of heparinized Cuprophan also increased in
time but did not significantly differ from the TCC con-
centration induced by the test tube (polystyrene)
alone.
Reduced complement activation by the heparinized
membranes can be ascribed to two different mecha-
nisms. First, it is generally assumed that the hydroxyl
groups of cellulose trigger the alternative pathway of
the complement system by covalently binding of
C3b.31,32 Therefore, masking or modifying of the hy-
droxyl groups of cellulose will reduce complement ac-
tivation, which indeed has been observed by many
investigators.31–36 Heparinization will also mask and
modify the hydroxyl groups of Cuprophan, thereby
passively reducing complement activation. Second,
surface-immobilized heparin may also play an active
role in reducing complement activation. As shown by
Kazatchkine et al.,37 immobilized heparin prevents the
formation of the alternative pathway C3 amplification
convertase, C3bBb, by promoting the interaction of the
inhibiting proteins H and I with surface-bound C3b.
Fluid-phase concentration of TCC is considered to
be a good measure for complement activation.38–40 In
a previous study, we have shown that heparinization
of Cuprophan by means of the CDI-activation proce-
dure strongly reduced the generation of fluid phase
C3a desarg.16 Most frequently, fluid phase C3a desarg
and C5a desarg concentrations are measured to quan-
tify the degree of complement activation. However,
care must be exercised to interpret the results of these
measurements, because biomaterials can absorb these
anaphylatoxins to different degrees depending on the
surface characteristics of the materials under investi-
gation.4,41–43 It has even been reported that in certain
cases immobilized heparin has a high affinity for bind-
ing C3a.41,44 Deppisch et al.39 showed that TCC does
not readily adsorb onto biomaterials. For heparinized
materials, however, adsorption of TCC has not been
investigated in detail, although Pekna et al.,45 who
studied complement activation by poly(methyl meth-
acrylate) and heparinized poly(methyl methacrylate),
showed that total C3 activation and fluid phase TCC
generation correlated well. Nevertheless, it is possible
that based on the results presented in this study, the
anticomplement activity of heparin immobilized onto
Cuprophan is overestimated. Adsorption of comple-
ment factors onto the membranes will therefore be the
subject of future investigations.
Heparinization does not significantly affect the
mass transfer coefficients for model solutes with mo-
lecular weights up to 12,000, except for SBP. The per-
meability of Cuprophan for SBP was slightly de-
creased after heparinization (Table II). The reduction
of the permeability for SBP by heparinization is prob-
ably due to the negative charges of both SBP and hep-
arin at physiologic conditions. Electrostatic repulsion
will limit the diffusion of negatively charged SBP
through the membrane onto which negatively charged
heparin is immobilized.
Ultrafiltration experiments showed that hepariniza-
tion increased the water permeability from 300 ± 4
mL/h × cm2 to 385 ± 11 mL/h × cm2 at a pressure of 3
bar. The increase is most likely because heparin is im-
mobilized in the pores of the membranes, which re-
sults in an increase of the swelling of the membrane in
Figure 2. Generation of fluid-phase TCC induced by: un-
treated Cuprophan: ●––; heparinized Cuprophan: m––; test
tube (polystyrene) alone: n––. Membranes with a surface area
of 3.9 cm were added to 500 mL of serum at 37°C. The con-
centration of TCC in serum was measured by means of an
ELISA (n = 3, ±SD).
TABLE II
Mass Transfer Coefficients of Various Solutes for
Untreated and Heparinized Cuprophan (n > 4, ±SD)
Solute
Ko (10
−3 cm/min)
Untreated
Cuprophan
Heparinized
Cuprophan
Urea 17.4 ± 0.9 17.9 ± 1.5
Phosphate 17.8 ± 1.5 18.3 ± 1.6
Creatinine 11.0 ± 0.6 12.1 ± 1.1
Glucose 7.36 ± 0.42 8.63 ± 0.89
Sucrose 5.06 ± 0.39 4.94 ± 0.33
SBP 3.93 ± 0.25 2.90 ± 0.21
Vitamin B12 1.73 ± 0.09 1.78 ± 0.16
Inulin 0.51 ± 0.03 0.42 ± 0.07
Cytochrome C 0.021 ± 0.002 0.026 ± 0.005
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water. A higher water permeability may require slight
adjustments of the conditions during hemodialysis.
These adjustments, however, are only very moderate
compared to those required when synthetic membranes
(e.g., polyacrylonitrile copolymer, polysulfone) are used.
Synthetic membranes exhibit an ultrafiltration rate more
than 10 times higher than that of cellulosic mem-
branes5,46,47 and require special precautions to prevent
excessive ultrafiltration during hemodialysis.5
Crosslinking of the membrane will result in a de-
creased permeability. In a control experiment a solu-
tion of CDI in formamide was added to Cuprophan.
By this treatment, the membrane became very brittle,
indicating crosslinking (data not shown). Crosslinking
is likely to occur by CDI activation of part of the hy-
droxyl groups of Cuprophan followed by the forma-
tion of carbonate crosslinks, which results from the
reaction between the activated hydroxyl groups and
other hydroxyl groups of Cuprophan.48 During the
heparinization procedure, heparin is activated with
CDI in the absence of Cuprophan until all CDI has
been consumed.22 Therefore, CDI is not contacted
with the membrane and the crosslinking reaction as
described above will not occur. This is confirmed by
the results of the permeability experiments. It is likely,
however, that more than one CDI-activated group per
heparin molecule had reacted with the hydroxyl
groups of Cuprophan, thus forming crosslinks. Ap-
parently, these type of crosslinks do not affect the per-
meability of the membrane.
The stability of the heparin–Cuprophan linkage was
studied by incubating heparinized Cuprophan in PBS
at 37°C up to 6 h. The release of heparin from the
membrane was evident (Fig. 3). During activation of
heparin with CDI, carboxylic acid and/or hydroxyl
groups of heparin react with CDI to form imidazolyl
amide and imidazolyl carbamate groups, respec-
tively.48 After contact with Cuprophan, these acti-
vated groups react with the hydroxyl groups of the
membrane to form ester and/or carbonate bonds, re-
spectively.48 The carbonyl groups of these bonds give
rise to an absorption at 1740 cm−1. FTIR spectroscopy
revealed that at prolonged incubation times of hepa-
rinized Cuprophan in PBS at 37°C (1 week), the inten-
sity of the absorption at 1740 cm−1 clearly reduces,
indicating that the release of heparin was caused by
the hydrolysis of covalent bonds between heparin and
Cuprophan and not by the diffusion of physically
bound heparin from the membrane (data not shown).
The release of heparin from the membrane plotted
as a fuction of the incubation time yields a straight line
(Fig. 3). This line does not cross the origin. Apparently,
there is a burst effect in the release of heparin during
the first 1 or 2 h of incubation. The following mecha-
nism can be proposed to explain this behavior. Prior to
the release experiment, the membranes were incu-
bated in PBS at 4°C for 16 h. During that time, some
hydrolysis of the covalent bonds between heparin and
Cuprophan will take place. Hydrolysis will result in a
release of heparin from the membrane. However, part
of the heparin which is no longer covalently linked
may be physically entrapped in the pores of the mem-
brane. When the membrane is transferred into PBS of
37°C, the swelling of the membrane will increase. The
increased swelling may facilitate the release of phys-
cially entrapped heparin, resulting in a burst effect.
Assuming that the stability of the heparin–
Cuprophan linkage is the same in blood as in PBS, the
clinical relevance of the stability studies can be evalu-
ated. Clinically applied dialyzers have a membrane
surface area of 1.0–1.5 m2; the dialysis time is usually
4 h. After 4 h of incubation in PBS at 37°C, 33.3 ± 1.7
mU of heparin/cm2 was released from the membrane.
This amount of released heparin seems very large
compared with the activity of immobilized heparin as
measured by means of the thrombin inactivation assay
(12.4 ± 4.2 mU/cm2). However, the activity of released
heparin cannot be compared with the activity of the
membrane. As mentioned, a large amount of heparin
is immobilized in the pores of the membrane and does
not contribute to the anticoagulant activity. As indi-
cated above, the hydrolysis of covalent bonds between
heparin and Cuprophan resulting in a release of hep-
arin is not limited to the surface but also occurs in the
pores of the membrane. Most likely, the relative
amount of heparin released from the surface and from
the pores of the membrane will be the same. There-
fore, most of the released heparin had not contributed
to the anticoagulant activity of the membrane. Fur-
thermore, because immobilized heparin exhibits a
Figure 3. Release of heparin from heparinized Cuprophan
incubated in PBS at 37°C. The concentration of heparin in
PBS was measured by means of an APPT assay (n = 8, ±DS).
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lower activity than heparin in solution, the activity of
the fraction of heparin which is released from the sur-
face as measured in the release experiments will be
higher than its activity when it is still immobilized and
measured by means of the thrombin inactivation as-
say. In a previous study,22 heparin was activated with
CDI after which the activated groups were hydro-
lyzed. It was shown that the activity of heparin was
not affected by this treatment. Therefore, it can be as-
sumed that heparin, before being used for hepariniza-
tion, has the same activity as heparin released from
the membrane. Thus, the amount of released heparin
can be expressed as a percentage of the original
amount of immobilized heparin. After 4 h of incuba-
tion in PBS at 37°C, a release of 0.25% can be calcu-
lated. Because 99.75% of the original amount of hep-
arin is still immobilized, a significant decrease of the
blood compatibility is not expected.
After 4 h of incubation in PBS at 37°C, 33.3 ± 1.7 mU
of heparin/cm2 was released from the membrane. For
a membrane surface area of 1.0–1.5 m2, this would
mean that 330–500 U of heparin will be released from
the membrane during 4 h of hemodialysis. A release of
330–500 U of heparin is much less than 4000–15,000 U
of heparin, which is systemically administered during
hemodialysis2 and is not expected to cause any unde-
sired effects. The release of heparin may even be re-
duced when the burst effect as described above can be
prevented. This may be achieved by rinsing the mem-
brane with an aqueous solution at 37°C prior to he-
modialysis, which is usually done in clinical practice.
CONCLUSIONS
The results of the present study clearly show that
heparin immobilized onto Cuprophan hemodialysis
membranes by means of the CDI-activation procedure
retains part of its biologic activities as expressed in the
thrombin inactivation and TCC assays. Furthermore,
the heparinization procedure does not have an ad-
verse effect on the permeability of the membrane. The
release of heparin from the membrane upon incuba-
tion in PBS is very low compared to the amount of
heparin systemically administered during hemodialy-
sis. Therefore it can be concluded that Cuprophan
membranes heparinized by means of the CDI-
activation procedure are highly promising for appli-
cation in hemodialyzers to be used for the treatment of
patients with reduced, or without systemic adminis-
tration of, heparin.
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